8-K: Abeona Therapeutics Reports Full Year 2024 Financial Results and Provides Regulatory Update for Pz-cel

Abeona Therapeutics announced its full year 2024 financial results, progress in the FDA review of pz-cel, and commercial launch plans, targeting the first patient treatment in 3Q 2025 if approved.

Summary

• Abeona Therapeutics reported its financial results for the full year 2024 and provided an update on the regulatory review and commercial launch plans for prademagene zamikeracel (pz-cel).
• The FDA has granted priority review for pz-cel with a PDUFA target action date of April 29, 2025.
• The company anticipates treating the first patient with pz-cel in the third quarter of 2025, pending FDA approval.
• Abeona's cash, cash equivalents, short-term investments, and restricted cash totaled $98.1 million as of December 31, 2024, compared to $52.6 million as of December 31, 2023.
• The company estimates its current resources are sufficient to fund operations into 2026, before considering potential revenue from pz-cel sales or proceeds from a Priority Review Voucher (PRV).
• Research and development expenses for 2024 were $34.4 million, compared to $31.1 million in 2023, due to increased headcount for manufacturing capacity expansion.
• General and administrative expenses increased to $29.9 million in 2024 from $19.0 million in 2023, primarily due to commercial launch preparation costs.
• The net loss for 2024 was $63.7 million, or $1.55 loss per common share, compared to a net loss of $54.2 million, or $2.53 loss per common share, in 2023.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the progress with pz-cel's regulatory review and the company's strong cash position. However, the increased net loss and dependence on pz-cel's approval temper the overall optimism.

Positives

• The FDA granted priority review for pz-cel, indicating a potentially faster approval timeline.
• Abeona has a strong cash position of $98.1 million, providing financial stability.
• The company anticipates its current resources will fund operations into 2026.
• Abeona obtained two additional patents for pz-cel, extending patent protection to June 2037 and July 2040.
• Ultragenyx submitted a BLA to the FDA seeking accelerated approval for UX111 (formerly ABO-102) AAV gene therapy as a treatment for patients with Sanfilippo syndrome type A (MPS IIIA).
• In February 2025, Ultragenyx announced FDA acceptance and Priority Review of the UX111 BLA with a PDUFA date of August 18, 2025.

Negatives

• Abeona reported a net loss of $63.7 million for the full year 2024, an increase from the $54.2 million loss in 2023.
• The company's increased general and administrative expenses are primarily due to commercial launch preparation costs, indicating significant investment without guaranteed returns.

Risks

• The approval of pz-cel is not guaranteed, and the FDA could require additional data or reject the BLA.
• Commercial launch preparations require significant investment, and the success of the launch depends on market acceptance and reimbursement.
• The company's future revenue is dependent on the approval and successful commercialization of pz-cel.
• The company's estimates regarding expenses, future revenues, capital requirements, and needs for additional financing may not be accurate.

Future Outlook

Abeona anticipates potential FDA approval of pz-cel and plans for commercial launch, targeting the first patient treatment in 3Q 2025. The company estimates its current resources are sufficient to fund operations into 2026, before considering potential revenue from pz-cel sales or proceeds from a Priority Review Voucher (PRV).

Management Comments

• The RDEB community continues to highlight the unmet medical need for new therapies that could provide long-lasting healing and pain reduction, even in tough large, chronic RDEB wounds, said Vish Seshadri, Chief Executive Officer of Abeona.

Industry Context

Abeona's focus on cell and gene therapies for rare diseases aligns with the broader industry trend of developing innovative treatments for unmet medical needs. The progress of Ultragenyx's UX111, a partnered program, also reflects the industry's interest in AAV gene therapies for genetic disorders.

Comparison to Industry Standards

• Abeona's focus on rare diseases is similar to companies like BioMarin Pharmaceutical and Sarepta Therapeutics, which also develop therapies for genetic disorders.
• The development of pz-cel for RDEB is comparable to Krystal Biotech's Vyjuvek, another gene therapy for the same condition, highlighting the competitive landscape.
• The company's cash runway into 2026 is a positive sign, but it's crucial to compare its cash burn rate and R&D spending with peers to assess its financial efficiency.

Stakeholder Impact

• Shareholders: The potential approval and commercialization of pz-cel could significantly increase shareholder value.
• Patients: Patients with RDEB could benefit from a new treatment option that provides long-lasting healing and pain reduction.
• Employees: The company's expansion of manufacturing capacity and commercialization efforts could create new job opportunities.
• Creditors: The company's strong cash position reduces the risk of default on its debt obligations.

Next Steps

• Abeona will continue working with the FDA to finalize the review of its BLA for pz-cel.
• The company will continue its commercialization efforts in anticipation of potential FDA approval of pz-cel.
• Abeona will continue to develop AAV-based gene therapies for ophthalmic diseases.

Key Dates

Keywords

pz-cel, RDEB, Abeona Therapeutics, Financial Results, FDA, Regulatory Update, Commercial Launch, Gene Therapy, Biologics License Application, PDUFA